GlassScriptPhysician profile
Marioara C Bodea
NPI 1952329310
$5,371.83
in general payments reported to CMS, 2019-2025
36 companies · $556 in 2025
The $556 reported for 2025 was more than what 80% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,092 · 2020: $612 · 2021: $1,077 · 2022: $961 · 2023: $717 · 2024: $356 · 2025: $556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,629.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,038.90 | 2019-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $794.46 | 2019-2025 | Belbuca, Xtampza |
| Lundbeck LLC | $527.62 | 2021-2025 | Vyepti |
| Pfizer INC. | $357.02 | 2019-2025 | |
| Redhill Biopharma INC. | $339.20 | 2020-2022 | |
| Boston Scientific Corporation | $295.28 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Scilex Pharmaceuticals INC. | $205.88 | 2019-2022 | |
| Assertio Therapeutics, INC. | $197.30 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $175.14 | 2019-2021 | |
| Amgen INC. | $161.06 | 2021-2022 | |
| Abbvie INC. | $135.60 | 2023-2025 | Ubrelvy, Qulipta |
| Vertex Pharmaceuticals Incorporated | $124.04 | 2025 | |
| Daiichi Sankyo INC. | $117.35 | 2019 | |
| Ibsa Pharma INC. | $104.07 | 2020-2021 | |
| Almatica Pharma LLC | $96.14 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $76.37 | 2019 | |
| Baudax Bio INC. | $65.73 | 2020 | |
| Grt US Holding, INC. | $64.94 | 2021-2022 | |
| Virtus Pharmaceuticals LLC | $56.70 | 2021-2025 | Levorphanol Tartrate |
| Takeda Pharmaceuticals U.S.A., INC. | $48.84 | 2019 | |
| Sanofi-Aventis U.S. LLC | $46.48 | 2021-2022 | |
| Valinor Pharma, LLC | $43.73 | 2025 | Movantik |
| Teva Pharmaceuticals USA, INC. | $41.80 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $37.03 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.20 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $26.97 | 2021 | |
| Arbor Pharmaceuticals, INC. | $24.24 | 2019 | |
| Abbott Laboratories | $21.57 | 2024 | Eterna |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.21 | 2019 | |
| Sentynl Therapeutics, INC. | $16.99 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.58 | 2023 | Quviviq |
| Biogen, INC. | $15.91 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.59 | 2023 | Seglentis |
| Zimmer Biomet Holdings, INC. | $11.85 | 2019 | |
| Shionogi INC | $10.79 | 2019 | |
| Forte Bio-Pharma LLC | $10.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marioara Bodea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.